INTRODUCTION

'Epilepsy' is the commonest neuropsychiatric disorder characterized by paroxysmal cerebral dysrhythmia, manifesting as brief episodes (seizures) of loss or disturbance of consciousness, with or without characteristic body movements (convulsions) with sensory or psychiatric phenomena [1]. There are about 50 million epileptic patients worldwide of whom up to 75% are living in the poor socio-economic background with little or minimal access to medical services or therapy [2].

Seizures can be defined as brief episodes of signs and symptoms due to abnormal, excessive synchronous neuronal activity in the brain. Epilepsy can be idiopathic or secondary to infection, neoplasm or head injury. In some case, it may be hereditary [3]. Epilepsy is a major public health issue in many nations. Despite the massive scale of the problem and much research undertaken therapy of epilepsy remains poorly understood [4].

Drug treatment of seizures/epilepsy at present is rather symptomatic. Drugs used for preventing the development of epilepsy or its cure are rather uncertain. Presently around 20 approved allopathic drugs and several non-pharmacological options are available to treat epilepsy, but about 30 percent of the patients are refractory to these treatments. Research is undertaken to identify newer drugs for both symptomatic and preventive therapies [5]. Due to heterogeneity and limited understanding of this disease, discovery, and development of anti-epileptic drugs is difficult [4].

Many indigenous medical plants which are safer and well tolerated are used since ages for treating neurological diseases including epilepsy. *Mimosa pudica* plant belonging to the family Mimosaceae is known as 'sensitive plant' in English and 'lajvanti' or 'chuimi' in local Hindi language. The plant is distributed throughout India. The leaves are bifoliate, obovate, obtuse or cuneate at the base, stalked, dentate, shiny with a bluish tinge. The young leaves are downy and the underside of the leaflets is more so. The flowers are yellow and occur in racemes along the leaf sheaths. The fruits are brick-colored pods, flat and straw-colored consisting of 3-5 one-seeded segments [6].

*Mimosa pudica* contains mimosine [7] which is a toxic alkaloid. Adrenalin like substance has been identified in the extract of its leaves. Some workers have reported the presence of crocetin dimethyl easter in the extract of the plant. Roots contain tannin. Seeds contain a mucilage which is composed of d-xylose and d-glucuronic acid. The plant is also reported to contain tubuline, and a new class of phytohormone 'turgorines'. *Mimosa pudica* leaves extract is proven to contain various bioactive components such as terpenoids, flavonoids, glycosides, alkaloids, quinines, phenols, tannins, saponins and coumarins [8].

Ayurveda has proved that its root is bitter, acrid, coolant, alepsumpheric and used in the treatment of leprosy, dysentery, vaginal and uterine complaints, inflammations, asthma, leucoderma, fatigue and blood diseases [8]. It is also used for the treatment of anxiety and depression [9]. Alcoholic extract of *Mimosa pudica* leaves has been proved to possess anti-epileptic activity in previous studies [10]. Hence, the present study is undertaken with an alcoholic extract of *Mimosa pudica* root to explore its anti-epileptic potential.

MATERIALS AND METHODS

Chemicals

Ethanol, Pentylenetetrazole (PTZ, Sigma laboratory), Propylene glycol, Valproic acid (Sun pharmaceuticals).

Preparation of the extract

*Mimosa pudica* plant was collected along with roots from around Mysore district and authenticated by the Pharmacognosy department of JSS Pharmacy College, Mysore. The roots were separated and made into a coarse powder after a shade dry for 1 w. About 500gms of this powder was subjected to soxhlet extraction for 12 h using ethanol as a solvent. The extract was further concentrated using vacuum extractor for complete removal of the ethanol. The concentrated ethanol extract of *Mimosa pudica* root (EMPR) was dissolved in vehicle propylene glycol for oral administration to the animals.

EVALUATION OF ANTICONVULSANT ACTIVITY OF *MIMOSA PUDICA* ROOT LINN IN SWISS ALBINO MICE

PRATHIMA C., SHASHIKUMARA, THIPPESWAMY T., JAYANTHI M. K.

Dept. of Pharmacology, JSS Medical College (A Constituent College of JSS University), Mysore

Email: samsruthia@gmail.com

Received: 15 Mar 2016 Revised and Accepted: 22 Jul 2016

ABSTRACT

Objective: To evaluate the anticonvulsant activity of ethanolic extract of *Mimosa pudica* root (EMPR) in experimental mice models.

Methods: Ethanolic extract of root parts of *Mimosa pudica* (EMPR) was prepared by a continuous method using soxhlet apparatus. EMPR in doses of 1000, 2000 mg/kg body wt along with valproate were administrated to albino mice by oral route and anti-epileptic activity was assessed by maximal electroshock (MES) and pentylenetetrazole (PTZ) induced seizure models. Abolition of tonic hind limb extension phase and an increase in seizure latency period, when compared to control group, were taken as a measure of protection in MES and PTZ induced convulsion models respectively.

Results: EMPR in the dose of 1000 and 2000 mg/kg body wt of mice showed significant anti-epileptic property in both MES and PTZ induced seizure models. There was a significant abolition of tonic hind limb extension phase in MES model. There was also a significant increase in seizure latency period in PTZ induced seizure model.

Conclusion: Results suggest that ethanolic extract of *Mimosa pudica* roots possess significant anti-epileptic activity. Further investigations are required to determine its active constituents and also its antiepileptic mechanism of action.

Keywords: Epilepsy, *Mimosa pudica* root extract, MES, PTZ model

MIMOSA PUDICA ROOT L. IN SWISS ALBINO MICE

© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

DOI: http://dx.doi.org/10.22159/ijpps.2016v8i9.11716
Animals
Adult Swiss albino mice of either sex weighing between 25 to 30 g were randomly selected from Central animal facility of JSS Medical College, Mysore. Animals were housed in 5 groups of 6 each, at an ambient temperature of 25±1°C with ad libitum access to food and water. The animals were fasted overnight just prior to the experiment but allowed free access to drinking water and food.

Grouping
Animals were randomly divided into 5 groups of 6 each.
Group 1: Control group received 0.25 ml propylene glycol p. o.
Group 2: Standard group received 200 mg/kg Valproate p. o. [11]
Group 3: Test group 1-received 1000 mg/kg of EMPR p. o.
Group 4: Test group 2-received 2000 mg/kg of EMPR p. o.
Group 5: Test group 3-received 1000 mg/kg of EMPR+70 mg/kg Valproate p. o.

All the drugs were administered orally for 5 d. The experimental drugs were administered one hour prior to induction of convulsion. The duration of tonic hind limb flexion (THLF), tonic hind limb extension (THLE), clonus and stupor noted. The vehicle treated mice showed the characteristic extensor tonus. The abolition of extensor (tonic) phase in drug treated groups was taken as criteria for their anticonvulsant activity.

Pentylenetetrazole (PTZ) induced seizures in mice
The albino mice were selected two weeks prior to the experiment by injecting the Pentylenetetrazole in a dose of 30 mg/kg intraperitoneally. Only those mice which showed clonic convulsions within 30 min during the preliminary examination were chosen for the study. After one hour of drug treatment, PTZ (70 mg/kg) was injected intraperitoneally and animals were observed for clonic convulsion episode. The clonic convulsions onset time, duration of clonic convulsions and postictal depression were observed for a period of 30 min.

Statistical analysis
The results were computed using GRAPH PRISM PAD version 5. One way Anova test followed by Post-hoc Tukey's multiple comparison tests were applied using the software. The differences between means were considered to be significant at p<0.05. The results were tabulated as below.

RESULTS
Phytochemical screening
Phytochemical screening of EMPR showed that the crude extract contained tannins, alkaloids, terpenoids, flavonoids, sterols, phenolic compounds and proteins.

Acute toxicity study
There was no mortality amongst the mice treated with the graded dose of EMPR up to a dose of 5000 mg/kg for a duration of 72 h. EMPR dose-dependently protected the mice against the MES and PTZ induced seizures. At the dose of 500 mg/kg and 4000 mg/kg p. o, the EMPR provided respectively 23% and 100% protection against seizures in PTZ induced seizures model. Based on the preliminary toxicity data and logarithmic dose-response curve, the EMPR dose of our further study was determined between 1000 to 4000 mg/kg.

MES-induced seizure model
The average duration of tonic hind limb flexion (THLF), tonic hind limb extension (THLE), clonus and stupor along with the percentages of inhibition of convulsions are presented in table 1.

Table 1: Effect of ethanolic extract of *M. Pudica* (EMPR) on MES-induced seizures in mice

<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment</th>
<th>Duration of THLF (sec)</th>
<th>Duration of THLE (sec)</th>
<th>Duration of clonus (sec)</th>
<th>Duration of stupor (sec)</th>
<th>% inhibition of convulsion</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Vehicle control</td>
<td>8.45±0.57</td>
<td>9.15±0.50</td>
<td>18.65±0.90</td>
<td>319.8±3.09</td>
<td>--</td>
</tr>
<tr>
<td>II</td>
<td>Valproate (200 mg/kg)</td>
<td>3.2±0.66***</td>
<td>1.98±0.28***</td>
<td>9.63±1.31***</td>
<td>38.53±3.67***</td>
<td>78.36%</td>
</tr>
<tr>
<td>III</td>
<td>EMPR (1000 mg/kg)</td>
<td>5.7±0.57**</td>
<td>5.27±0.14***</td>
<td>13.05±1.06*</td>
<td>118.2±2.84***</td>
<td>42.41%</td>
</tr>
<tr>
<td>IV</td>
<td>EMPR (2000 mg/kg)</td>
<td>4.53±0.37***</td>
<td>4.36±0.42***</td>
<td>12.03±1.4*</td>
<td>109.2±2.98***</td>
<td>52.35%</td>
</tr>
<tr>
<td>V</td>
<td>EMPR+Valproate</td>
<td>3.9±0.41****</td>
<td>2.14±0.26***</td>
<td>10.23±1.73***</td>
<td>92.33±3.11****</td>
<td>76.61%</td>
</tr>
</tbody>
</table>

Values are expressed as mean±SEM. Comparison between control v/s all the other groups. Statistical test done by one-way ANOVA followed by Post-hoc Tukey's multiple comparison test, *p<0.05; **p<0.01; *** p<0.001; ****p<0.0001.

Albino mice pretreated with EMPR at the doses of 1000 and 2000 mg/kg exhibited a significant delay in the onset time and also a significant decrease in duration of THLF, THLE, clonus and stupor phases when compared to the control group mice. The albino mice pretreated with EMPR at doses of 1000 and 2000 mg/kg also exhibited significant protection from convulsion induced by electroshock method in a dose-dependent manner. The animal group treatment with a combination of both 1000 mg/kg of EMPR and low dose (70 mg/kg) of valproate exhibited significant anti-epileptic activity comparable to the Standard Valproate (200 mg/kg) treated group.

Pentylenetetrazole (PTZ) induced seizure model
The average seizure latency time, duration of myoclonic jerks, Generalized clonic seizures and post-ictal depression along with the percentages of protection against convulsions are presented in table 2. Albino mice pretreated with EMPR at the doses of 1000 and 2000 mg/kg and the combination group exhibited a significant delay in the onset time of clonic seizures when compared to the control group mice. EMPR (1000 and 2000 mg/kg) treated mice also showed a significant decrease in number and duration of myoclonic jerks, clonic seizures and duration of postictal depression when...
compared to the control group mice. EMPR provided significant protection from convulsion induced by PTZ in a dose-dependent manner. The animal group treatment with a combination of both 1000 mg/kg of EMPR and low dose (70 mg/kg) of valproate exhibited a significant anti-epileptic activity even better than the Standard Valproate (200 mg/kg) treated group.

Table 2: Effect of ethanolic extract of M. Pudica L. (EMPR) on PTZ induced seizures in mice

<table>
<thead>
<tr>
<th>Group- treatment</th>
<th>Seizure latency period (sec)</th>
<th>Duration of of myoclonic jerks (sec)</th>
<th>Duration of clonic seizures (sec)</th>
<th>PID (sec)</th>
<th>% Protection</th>
</tr>
</thead>
<tbody>
<tr>
<td>I vehi cle control</td>
<td>308.6±32.58</td>
<td>6.72±0.68</td>
<td>14.2±0.66</td>
<td>8.12±</td>
<td>56.51%</td>
</tr>
<tr>
<td>II-Valproate</td>
<td>483±</td>
<td>1.68±0.21</td>
<td>10.98±</td>
<td>0.32±</td>
<td>31.1%</td>
</tr>
<tr>
<td>(200 mg/kg, p. o)</td>
<td>22.72****</td>
<td>0.66****</td>
<td>14.35****</td>
<td>9.34</td>
<td>65.48%</td>
</tr>
<tr>
<td>III-EMPR</td>
<td>404.5±</td>
<td>3.51±0.26</td>
<td>3.51±0.26</td>
<td>0.24****</td>
<td>79%</td>
</tr>
<tr>
<td>(1000 mg/kg, p. o)</td>
<td>17.49</td>
<td>1.3±0.17</td>
<td>8.6±</td>
<td>8.2****</td>
<td>79%</td>
</tr>
<tr>
<td>IV-EMPR</td>
<td>310.7±</td>
<td>1.02±0.21</td>
<td>5.059±</td>
<td>0.66****</td>
<td>5.1****</td>
</tr>
<tr>
<td>(200 mg/kg, p. o)</td>
<td>22.74****</td>
<td>0.24****</td>
<td>232.57±</td>
<td>510.7±</td>
<td>28.4%</td>
</tr>
<tr>
<td>V-EMPR+Valproate</td>
<td>554.3±</td>
<td>0.66****</td>
<td>322.6±9.82</td>
<td>5.1****</td>
<td>79%</td>
</tr>
<tr>
<td>(1000 mg/kg)</td>
<td>11.77****</td>
<td>3.51±0.26</td>
<td>1.68±0.21</td>
<td>6.72±0.68</td>
<td>56.51%</td>
</tr>
<tr>
<td>(70 mg/kg, p. o)</td>
<td>1.02±0.21</td>
<td>0.66****</td>
<td>8.12±</td>
<td>8.6±</td>
<td>31.1%</td>
</tr>
</tbody>
</table>

Values are expressed as mean±SEM. PID: Postictal depression; Comparison between control vs all the other groups. Statistical test is done by one-way ANOVA followed by Post-hoc Tukey’s multiple comparison tests. *p<0.05, **p<0.01, *** p<0.001; ****p<0.0001.

**DISCUSSION**

Epilepsy is a group of chronic neurological disorder characterized by episodes of convulsive seizures, sensory disturbance, altered consciousness or all of these symptoms resulting from a brain dysfunction or an abnormal discharge of cerebral neurons [15]. The currently available AEDs for the therapy of epilepsy are associated with various side effects like teratogenicity and chronic toxicities of various organs. This has necessitated the need for a safer alternative indigenous drugs for the pharmacotherapy of epilepsy.

Various plant preparations are used by the folklore and the tribals for the treatment of common disease conditions including epilepsy. *Mimosa pudica* is one of those commonly seen plants which is known to possess analgesic, anti-anxiety, antidepressant, anti-asthmatic and aphrodisiac properties [8]. Phytochemical screening of the EMPR extract revealed the presence of tannins, alkaloids, terpenoids, flavonoids, sterols, phenolic compounds and proteins. The data obtained from the present study demonstrated that EMPR significantly inhibited the convulsions induced by MES and PTZ. GABA is known to be a major inhibitory neurotransmitter in the brain and glutamate the excitatory neurotransmitter. GABA acts on GABA receptors while glutamate acts on NMDA and non-NMDA receptors. These receptors are known to modify various ion channels like Na+, K+, Ca++or Cl- and thereby influence the neuronal synapses is known to be one of the important factors for epileptogenesis [14].

MES test in mice primarily indicates the compounds which are effective in grand mal epilepsy. The tonic extension of the hind limb evoked by electrical stimuli is suppressed by anti-epileptics. Anti-epileptic drugs that block MES-induced seizure are known to act by blocking the seizure spread [17]. The drugs which antagonize the PTZ induced convulsions are known to be effective in petitmal epilepsy. PTZ is known to possess GABA antagonistic activity [18]. The antiepileptic drugs diazepam and phenobarbitone are proved to produce their antiepileptic effects by enhancing GABA- mediated chloride channels in animal models of anxiety, sedation and convulsion. Certain triterpenic steroids are reported to possess anticonvulsant activity in MES and PTZ experimental seizure models [21]. Further studies are required for isolation of bioactive principles responsible for these activities. These findings justify the traditional use of this plant in the control and treatment of convulsions and epilepsy.

**CONCLUSION**

It can be concluded from the study that the ethanolic extract *Mimosa pudica* root (EMPR) exhibited significant antiepileptic activity in both MES and PTZ induced seizure models. Further studies are needed to evaluate the precise mechanism/s, bioactive principles and safety profile of the plant as a medicinal remedy for convulsive disorders.

**CONFLICT OF INTERESTS**

Declared none

**REFERENCES**

5. McNamara JD. Pharmacotherapy of epilepsies. In: Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's the

How to cite this article